8ZHD の概要
エントリーDOI | 10.2210/pdb8zhd/pdb |
EMDBエントリー | 60099 |
分子名称 | Spike glycoprotein,Fibritin,Expression Tag, Heavy chain of R1-26 Fab, Light chain of R1-26 Fab, ... (5 entities in total) |
機能のキーワード | spike protein, rbd, antibody, fab, viral protein, viral protein-immune system complex, viral protein/immune system |
由来する生物種 | Severe acute respiratory syndrome coronavirus 2 詳細 |
タンパク質・核酸の鎖数 | 7 |
化学式量合計 | 539696.95 |
構造登録者 | |
主引用文献 | Yan, Q.,Gao, X.,Liu, B.,Hou, R.,He, P.,Ma, Y.,Zhang, Y.,Zhang, Y.,Li, Z.,Chen, Q.,Wang, J.,Huang, X.,Liang, H.,Zheng, H.,Yao, Y.,Chen, X.,Niu, X.,He, J.,Chen, L.,Zhao, J.,Xiong, X. Antibodies utilizing VL6-57 light chains target a convergent cryptic epitope on SARS-CoV-2 spike protein and potentially drive the genesis of Omicron variants. Nat Commun, 15:7585-7585, 2024 Cited by PubMed Abstract: Continued evolution of SARS-CoV-2 generates variants to challenge antibody immunity established by infection and vaccination. A connection between population immunity and genesis of virus variants has long been suggested but its molecular basis remains poorly understood. Here, we identify a class of SARS-CoV-2 neutralizing public antibodies defined by their shared usage of VL6-57 light chains. Although heavy chains of diverse genotypes are utilized, convergent HCDR3 rearrangements have been observed among these public antibodies to cooperate with germline VL6-57 LCDRs to target a convergent epitope defined by RBD residues S371-S373-S375. Antibody repertoire analysis identifies that this class of VL6-57 antibodies is present in SARS-CoV-2-naive individuals and is clonally expanded in most COVID-19 patients. We confirm that Omicron-specific substitutions at S371, S373 and S375 mediate escape of antibodies of the VL6-57 class. These findings support that this class of public antibodies constitutes a potential immune pressure promoting the introduction of S371L/F-S373P-S375F in Omicron variants. The results provide further molecular evidence to support that antigenic evolution of SARS-CoV-2 is driven by antibody mediated population immunity. PubMed: 39217172DOI: 10.1038/s41467-024-51770-3 主引用文献が同じPDBエントリー |
実験手法 | ELECTRON MICROSCOPY (3.41 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード
